Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
106M
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
50.2M
-
Shares change
-
+2.98M
-
Total reported value, excl. options
-
$770M
-
Value change
-
+$30.5M
-
Put/Call ratio
-
4.13
-
Number of buys
-
66
-
Number of sells
-
-54
-
Price
-
$15.34
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q3 2023
155 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q3 2023.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.2M shares
of 106M outstanding shares and own 47.42% of the company stock.
Largest 10 shareholders include Paradigm Biocapital Advisors LP (3.68M shares), VR Adviser, LLC (3.08M shares), BlackRock Inc. (2.99M shares), Deep Track Capital, LP (2.96M shares), STATE STREET CORP (2.94M shares), VANGUARD GROUP INC (2.45M shares), COMMODORE CAPITAL LP (2.2M shares), RA CAPITAL MANAGEMENT, L.P. (2.01M shares), ALLIANCEBERNSTEIN L.P. (1.89M shares), and BRAIDWELL LP (1.74M shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.